This segment focuses on assessing bleeding and variceal risk before initiating anti-VEGF therapy with atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (HCC).
Midhun Malla, MD, presents real-world data for Team Deep-Dish Pizza, reviewing a multicenter retrospective study comparing frontline atezolizumab plus bevacizumab with durvalumab-based therapy in advanced hepatocellular carcinoma (HCC).
Ronan W. Hsieh, MD, presents the CheckMate 9DW trial for Team Chicago Hot Dog, reviewing the phase 3 study of nivolumab plus ipilimumab versus investigator's choice of lenvatinib or sorafenib in first-line unresectable hepatocellular carcinoma (HCC).
The panel discusses ipilimumab dosing and the management of immune-related toxicity with nivolumab plus ipilimumab in advanced hepatocellular carcinoma (HCC).
James J. Harding, MD, presents the SIERRA study for Team Deep-Dish Pizza, reviewing the phase 3b, single-arm trial of the STRIDE regimen, tremelimumab plus durvalumab, in first-line unresectable hepatocellular carcinoma (HCC) with poor-prognosis features.
The panel discusses whether the SIERRA safety data support using the STRIDE regimen, tremelimumab plus durvalumab, in patients typically excluded from frontline hepatocellular carcinoma (HCC) trials.
Jun Gong, MD, presents the EMERALD-1 trial for Team Chicago Hot Dog, reviewing the phase 3, randomized, double-blind study of transarterial chemoembolization (TACE) with durvalumab, with or without bevacizumab, in unresectable hepatocellular carcinoma (HCC) amenable to embolization.
